Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation

Current Alzheimer Research

Volumn 9, Issue 8, 2012, Pages 881-889

  Ribeiro, Carlos A ^a,f   Santana, Isabel ^b,c,d   Oliveira, Catarina ^b,c,d   Baldeiras, Inês ^c,d   Moreira, Jorge ^e   Saraiva, Maria João ^a,f   Cardoso, Isabel ^a,g  

^a UNIVERSITY OF PORTO   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e LabMED center   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

Author keywords

Alzheimer's disease; ApoE; Biomarker; Disease severity; Estradiol; Plasma; Thyroxine; Transthyretin

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ESTRADIOL; PREALBUMIN; THYROXINE;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; GENETIC ANALYSIS; GROUPS BY AGE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BINDING; SEX DIFFERENCE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREALBUMIN; SEX CHARACTERISTICS;

EID: 84867714724     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803251057     Document Type: Article

References (58)

1. El Sankari S, Gondry-Jouet C, Fichten A, Godefroy O, Serot JM, Deramond H, et al. Cerebrospinal fluid and blood flow in mild cognitive impairment and Alzheimer's disease: a differential diagnosis from idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 8(1): 12 (2011).
2. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 58(12): 1985-92 (2001).
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123): 921-3 (1993).
4. Sparks DL. Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Abeta through the liver. Curr Alzheimer Res 4(2): 165-9 (2007).
5. Malito E, Hulse RE, Tang WJ. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci 65(16): 2574-85 (2008).
6. Chauhan VP, Ray I, Chauhan A, Wisniewski HM. Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 258(2): 241-6 (1999).
7. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91(18): 8368-72 (1994).
8. Costa R, Gonçalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582(6): 936-42 (2008a).
9. Schwarzman AL, Goldgaber D. Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 199: 146-60 (1996).
10. Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem Sep 260(21): 11793-8 (1985).
11. Robbins J. Thyroid hormone transport proteins and the physiology of hormone binding. In: Braverman LE, and Utiger, R.D., editor. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 6th edition ed. New York: J.B. Lippincott Co.; 1991. p. 111-25.
12. Loun B, Hage DS. Characterization of thyroxine-albumin binding using high-performance affinity chromatography. I. Interactions at the warfarin and indole sites of albumin. J Chromatogr 579(2): 225-35 (1992).
13. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36(4): 411-23 (2007).
14. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS One 3(8): e2899 (2008b).
15. Liz MA, Faro CJ, Saraiva MJ, Sousa MM. Transthyretin, a new cryptic protease. J Biol Chem 279(20): 21431-8 (2004).
16. Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. Neurosurg Psychiatry 63(4): 506-8 (1997).
17. Gloeckner S, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14(1): 17-25 (2008).
18. Hansson SF, Andréasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16(2): 389-97 (2009).
19. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9(3): 293-348 (2006).
20. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, Hsu WC, et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 405(1-2): 143-7 (2009).
21. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13(5): 611-5 (2002).
22. Han S, Jung E, Sohn J, Hong HJ, Hong HS, Kim JW, et al. Human Serum Transthyretin Levels Correlate Inversely with Alzheimer's Disease. J Alzheimers Dis 25(1): 77-84 (2011).
23. Velayudhan L, Killick R, Hye A, Kinsey A, Güentert A, Lynham S, et al. Plasma Transthyretin as a Candidate Marker for Alzheimer's Disease. Alzheimers Dis 28(2): 369-75(2012).
24. Kaplan P. Neurologic Disease in Women. New York: Demos Medical Publishing, Inc; 2006.
25. Candore G, Balistreri CR, Grimaldi MP, Vasto S, Listì F, Chiappelli M, et al. Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease. Ann NY Acad Sci 1089: 472-86 (2006).
26. Quintela T, Gonçalves I, Baltazar G, Alves CH, Saraiva MJ, Santos CR. 17beta-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway. Cell Mol Neurobiol 29(4): 475-83 (2009).
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-98 (1975).
28. Guerreiro M. Avaliação Breve do Estado Mental: Escalas e Testes na Demência. Grupo de Estudos de Envelhecimento Cerebral e Demência: 27-32 (2003).
29. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 19(3): 448-50 (1983).
30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141(11): 1356-64 (1984).
31. Guerreiro M. Escalas e Testes na Demência. Grupo de Estudos de Envelhecimento Cerebral e Demência: 33-49 (2003).
32. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 24(4): 637-9 (1988).
33. Guerreiro M. Contribution of Neuropsychology to the Study of Dementias. Lisbon, Portugal: Faculty of Medicine of Lisbon; 1988.
34. Association AP. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association(4 rd ed) (1994).
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-44 (1984).
36. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9): 1133-42 (2001).
37. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. Neurosci Methods 53(2): 125-7 (1994).
38. Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 249(3): 662-8 (1997).
39. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res.
40. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and nondemented elderly subjects. Neurol Res. [Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't] 28(2): 155-63 (2006).
41. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ. Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 204(3): 212-4 (1996).
42. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, et al. Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging 32(2): 249-56 (2011).
43. Kunicki S, Richardson J, Mehta PD, Kim KS, Zorychta E. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 31(5): 409-15 (1998).
44. Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 103(3A): 11S-8S (1997).
45. Oliveira SM, Ribeiro CA, Cardoso I, Saraiva MJ. Gender-Dependent Transthyretin Modulation of Brain Amyloid-beta Levels: Evidence from a Mouse Model of Alzheimer's Disease. J Alzheimer's Dis: JAD Aug 12 (2011).
46. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65(6): 776-85 (2008).
47. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 425(2): 225-8 (1998).
48. Roses A. Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Ann NY Acad Sci Dec 802: 50-7 (1996).
49. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118(12): 4002-13 (2008).
50. Holtzman DM. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci 17(2): 147-55 (2001).
51. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 58(5): 681-93 (2008).
52. Quintas A, Saraiva MJ, Brito RM. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 418(3): 297-300 (1997).
53. Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ. Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6(3): 309-15 (1997).
54. Stuerenburg HJ, Arlt S, Mueller-Thomsen T. Free thyroxine, cognitive decline and depression in Alzheimer's disease. Neuro Endocrinol Lett 27(4): 535-7 (2006).
55. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 70(23): 2212-8 (2008).
56. Gonçalves I, Alves CH, Quintela T, Baltazar G, Socorro S, Saraiva MJ, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem 317(1-2): 137-42 (2008).
57. Amtul Z, Wang L, Westaway D, Rozmahel RF. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease. Neuroscience 169(2): 781-6 (2010).
58. Johnson AM. Low levels of plasma proteins: malnutrition or inflammation? Clin Chem Lab Med 37(2): 91-6 (1999).